Tvardi Therapeutics TVRD
NASDAQ TVRD
$1.05 +0.06 (+5.83%)
As of: Oct 21, 2026 · 9:35 AM EDT

Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025)

Updated

Tvardi Therapeutics' Cash from Restructuring came in at -$352,000 for Q2 2025.

Analysis

Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025) Analysis & Trends

For FY2024, Tvardi Therapeutics' Cash from Restructuring was $1.51 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,140.41 Bn 1,108.99 Bn 19.71 Bn
2 Johnson & Johnson 618.57 Bn 537.10 Bn 17.26 Bn
3 AbbVie 509.95 Bn 483.06 Bn 12.70 Bn
4 Merck 366.63 Bn 321.01 Bn 12.21 Bn
5 Novartis Ag 298.47 Bn 262.46 Bn 11.24 Bn
6 Astrazeneca 263.21 Bn 236.89 Bn 12.86 Bn
7 Amgen 236.71 Bn 192.11 Bn 7.24 Bn
8 Gilead Sciences 193.05 Bn 167.25 Bn 6.22 Bn
9 Pfizer 171.45 Bn 118.10 Bn 10.94 Bn
10 Tvardi Therapeutics 9.85 Mn -98.25 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -352,000.00
Mar 31, 2025 781,000.00
Dec 31, 2024 439,000.00
API Access

Tvardi Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=TVRD&period=max&api_key=YOUR_API_KEY